Name, + highest degree: Qingquan Li, Ph.D.
Position title: Professor/Ph.D. Student Supervisor
Email: 061101040@fudan.edu.cn
Phone: 86-21-51980037
Address: Room 419, research building, Zhangheng Road 826；
Department of pharmacology, school of pharmacy, Fudan University
My research focuses on tumor therapeutic resistance and tumor metastasis, in the perspective of tumor heterogeneity and tumor metabolism. I have made a series of works on the involvement of heterogeneous tumor subpopulations (CD110+, CDCP1+, TrkB+ and CD70+ subsets) in driving organ-specific metastasis and post-therapeutic recurrence. Also, I have been clarifying the essential role of various oncometabolites (lysine, methionine, uric acid, γ-aminobutyric acid, α-ketoglutaric acid and succinate), which induce signaling cascades, epigenetic remodeling and enzyme activation, during the development of tumor therapeutic resistance and distant metastasis. The intention is to provide specific diagnostic biomarkers and novel metabolic checkpoints to improve cancer outcomes in patients, and to work closely with clinicians to enable bench-to-bedside translation.
Tumor therapeutic resistance; Tumor metastasis; Tumor heterogeneity; Tumor metabolism
Education:
Bachelor Degree
09/1998 –07/2003, Fudan University, Preventive Medicine
Ph.D
09/2004 –06/2009, Fudan University, Pathology
Professional Experiences
07/2009 –04/2011, Fudan University, Department of Pathology, Lecturer
05/2011 –11/2015, Fudan University, Department of Pathology, Associate Professor
12/2015 –09/2019, Fudan University, Department of Pathology, Professor
08/2021 –present, Fudan University, Department of Pharmacology, Professor
Teaching Activities
Biochemistry, Molecular Biology, Pharmacology
Grants & Projects
1. National Natural Science Foundation of China (Grant No. 81874064), ‘m6A demethylation in CDCP1+ subpopulation determines metastatic recurrence in Kras-mutated colorectal carcinoma’, RMB630,000 for the entireprogram, 2019-2022.
2. National Natural Science Foundation of China (Grant No. 81572886), ‘The molecular mechanism of relapse and metastasis of triple negative breast cancer mediated by the TrkB+ subpopulation undergoing lysine catabolism’, RMB570,000 for the entireprogram, 2016-2019.
3. National Natural Science Foundation of China (Grant No. 81372350), ‘The involvement of CD70+ cancer stem cells in breast cancer metastasis’, RMB750,000 for the entireprogram, 2014-2017.
4. National Natural Science Foundation of China (Grant No. 81000957), ‘Regulation of self-renewal and tumorigenicity of breast cancer stem cells is mediated by epithelial-mesenchymal transition via BDNF-TrkB pathway’, RMB200,000 for the entireprogram, 2011-2013.
Awards & Honors
1. Henan Province Science and Technology Progress Second Prize, 2022.
2. The National Youth Talent Support Program, The Organization Department of the Central Commit, 2019.
3. Shanghai Academic/Technology Research Leader, 2019.
4. Army Science and Technology Progress Second Prize, 2017.
5. Shanghai Rising-Star of Science and Technology Committee, 2015.
6. Henan Province Science and Technology Progress Second Prize, 2014.
7. Shanghai Natural Science Third Prize, 2013.
Memberships
1. Vice Chairman of the “Pathology Expert Committee of the National Health Industry Enterprise Management Association”, 2023-2028.
2. Executive member of the“Intractable Cancer Committee of the China Medical Education Association”, 2018-2023.
3. Chairman of the “Translational Medicine Committee of Anorectal Branch of Chinese Medical Doctor Association”, 2019-2022.
4. Executive member of the “Anorectal Branch of Chinese Medical Doctor Association”,2019-2022.
5. Vice Chairman of the “Youth Committee of Anorectal Branch of Chinese Medical Doctor Association”,2019-2022.
6. Member of the “Clinical Guidelines Committee of Anorectal Branch of Chinese Medical Doctor Association”,2018-2021.
7. Member of the “Youth Committee of Cancer Precision Treatment Branch of China Anti-Cancer Association”, 2018-2021.
8. Vice Chairman of the “Pathology Expert Committee of the National Health Industry Enterprise Management Association”, 2016-2021.
9. Vice Chairman of the “Youth Committee of Anorectal Branch of Chinese Medical Doctor Association”,2016-2019.
10. Member of the “Anorectal Branch of Chinese Medical Doctor Association”,2016-2019.
Invited Presentations
1. The 1st China Congress on Experimental Medicine, Hangzhou, China, 2016. Tumor Heterogeneity and Tumor Diagnostics.
2. The 2ndChina Congress on Experimental Medicine, Fuzhou, China, 2017. Tumor Metabolic Heterogeneity in Malignant Progression.
3. The 8th China Annual Pathology Conference, Chengdu, China, 2018. The Involvement of Tumor Metabolism in Metastasis and Post-therapeutic Recurrence.
4. The 20th Shanghai International Colorectal Cancer Symposium, Shanghai, China, 2024. Tumor Metabolic Reprogramming Drives Immunotherapeutic Resistance in Colorectal Carcinoma.
Selected Publications（latest 5 yrs，<20 papers）
1. Zhang C, Du Z, Gao Y, Lim KS, Zhou W, Huang H, He H, Xiao J, Xu D, Li Q*(corresponding author). Methionine secreted by tumor-associated pericytes supports cancer stem cells in clear cell renal carcinoma. Cell Metabolism, 2024; 36(4):778-792.
2. Li Y, Zhang Y, Wang M, Su J, Dong X, Yang Y, Wang H, Li Q*(corresponding author). The mammalian actin elongation factor ENAH/MENA contributes to autophagosome formation via its actin regulatory function. Autophagy, 2024; 20(8):1798-1814.
3. Du Z, Su J, Lin S, Chen T, Gao W, Wang M, Li Y, Wei D, Hu Z, Gao C, Li Q*(corresponding author). Hydroxyphenylpyruvate dioxygenase is a metabolic immune checkpoint for UTX-deficient colorectal cancer. Gastroenterology. 2023; 164(7):1165-1179.
4. Wu Z, Su J, Li FL, Chen T, Mayner J, Engler A, Ma S, Li Q*(corresponding author), Guan K. YAP silencing by RB1 mutation is essential for small-cell lung cancer metastasis. Nat Communications. 2023; 14(1):5916.
5. Xu C, Gao Q, Wu Z, Lou W, Li X, Wang M, Wang N, Li Q*(corresponding author). Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas. Translational Oncology. 2022; 26:101540.
6. Zhang C, Chen L, Lou W, Su J, Huang J, Liu A, Xu Y, He H, Gao Y, Xu D, Li Q*(corresponding author). Aberrant activation of m6A demethylase FTO renders HIF2αlow/- clear cell renal cell carcinoma sensitive to BRD9 inhibitors. Science Translational Medicine, 2021; 13(613): eabf6045.
7. Yang C, Xu C, Li Z, Chen Y, Wu T, Hong H, Lu M, Jia Y, Yang Y, Liu X, Deng M, Chen Z, Li Q*(corresponding author), Lin Y, Zhou Y. Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3Kδ inhibitor: Design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2021; 223: 113661.
8. Lou W, Gao K, Xu C, Li Q*(corresponding author). Bromodomain-containing protein 9 is a prognostic biomarker associated with immune infiltrates and promotes tumor malignancy through activating notch signaling pathway in negative HIF-2α clear cell renal cell carcinoma. IUBMB Life. 2021; 73(11):1334-1347.
9. Gao W, Xu Y, Chen T, Du Z, Liu X, Hu Z, Wei D, Gao C, Zhang W, Li Q*(corresponding author). Targeting oxidative pentose phosphate pathway prevents recurrence in mutant Kras colorectal carcinomas. PLoS Biology, 2019; 17(8): e3000425.
10. Gao Y, Chen L, Du Z, Gao W, Wu Z, Liu X, Huang H, Xu D, Li Q*(corresponding author). Glutamate Decarboxylase 65 Signals through the Androgen Receptor to Promote Castration Resistance in Prostate Cancer. Cancer Research, 2019; 79(18): 4638-4649.
